Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TWST | 144 | neutral | 2/10 | Director Katryn Blake filed a Form 144 to sell 2,240 shares of Twist Bioscience common stock, valued at approximately $2 | Aug 12, 2026 |
| SGMOQ | 8-K | bearish | 9/10 | Sangamo Therapeutics, Inc. filed its first monthly operating report (MOR) with the Bankruptcy Court for the period June | Aug 12, 2026 |
| AMPH | CLUSTER | neutral | 2/10 | Two Amphastar insiders, Director Richard Prins and CFO William Peters, sold a combined $346K in open-market shares over | Aug 12, 2026 |
| MTEX | 8-K | bullish | 6/10 | Mannatech reported Q2 2026 results with net sales of $26.7M (+3.8% YoY), a return to profitability with net income of $1 | Aug 12, 2026 |
| ETST | 8-K | neutral | 3/10 | Earth Science Tech, Inc. (ETST) acquired Meduvo LLC, a California compounding pharmacy, in an immaterial related-party t | Aug 12, 2026 |
| NERV | 8-K | neutral | 2/10 | Minerva Neurosciences appointed Anthony Aliquo as Chief Accounting Officer, relieving CFO Fred Ahlholm of the principal | Aug 12, 2026 |
| DERM | 8-K | bullish | 6/10 | Journey Medical reported Q2 2026 revenue of $18.5M (+23% YoY), beating the $18.4M consensus, and a narrower GAAP net los | Aug 12, 2026 |
| ERAS | 3 | neutral | 2/10 | Charles S. Fuchs, President of R&D at Erasca, filed a Form 3 initial statement of beneficial ownership, indicating he be | Aug 12, 2026 |
| REPL | CLUSTER | bullish | 7/10 | A cluster of insider selling by the CMO, CFO, and CAO totaling ~$396K on August 10, 2026, occurred just one day after a | Aug 12, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | This is a routine procedural stipulation in the multi-district FreeStyle CGM consumer litigation against Abbott Diabetes | Aug 12, 2026 |
| INSM | CLUSTER | neutral | 4/10 | Insmed's COO and CMO sold a combined $33.1M in stock immediately following a blockbuster Q2 earnings beat (revenue $425. | Aug 12, 2026 |
| AMGN | COURT-RULING | neutral | 3/10 | Amgen's motion to remand two aflibercept (Eylea) patent infringement cases from the West Virginia MDL back to the Centra | Aug 12, 2026 |
| REGN | COURT-RULING | bullish | 5/10 | The court denied Amgen's motion to remand the aflibercept (Eylea) patent litigation back to the Central District of Cali | Aug 12, 2026 |
| BCAX | CLUSTER | neutral | 4/10 | Three top executives at Bicara Therapeutics (CEO, President/COO, CFO) executed same-day option exercises and open-market | Aug 12, 2026 |
| IMNM | CLUSTER | neutral | 4/10 | Two insiders at Immunome sold a total of $2.54M in shares over a week, led by the Chief Business Officer's $2.27M sale. | Aug 12, 2026 |
| ONC | CLUSTER | neutral | 4/10 | CEO John Oyler sold ~$51.8M worth of ONC shares over three days (Aug 10-12), and CFO Aaron Rosenberg sold $362K on Aug 3 | Aug 12, 2026 |
| AEON | PRESS-RELEASE | neutral | 4/10 | AEON Biopharma reported Q2 2026 EPS of -$0.02, significantly beating the consensus estimate of -$0.33, though this is a | Aug 12, 2026 |
| TRAX | PRESS-RELEASE | bullish | 6/10 | First Tracks Biotherapeutics reported Q2 2026 net loss of $33.4M ($0.95/share), narrower than the $42.4M loss in Q2 2025 | Aug 12, 2026 |
| RVPH | PRESS-RELEASE | neutral | 4/10 | Reviva Pharmaceuticals reported a Q2 2026 net loss of $2.4 million ($0.19 per share), narrower than the year-ago loss of | Aug 12, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Twist Bioscience CEO Emily Leproust sold $14.2M in stock on Aug 10, 2026, following the company's strong Q3 earnings bea | Aug 12, 2026 |
| ICLR | CLUSTER | neutral | 2/10 | A cluster of 20 insider sales by 6 directors at ICON PLC over a single day (Aug 11, 2026) totaling ~$1.0M, plus a separa | Aug 12, 2026 |
| TRAX | 8-K | bullish | 6/10 | First Tracks Biotherapeutics reported Q2 2026 net loss of $33.4M ($0.95/share), narrower than the $42.4M loss in Q2 2025 | Aug 12, 2026 |
| KLRA | 8-K | neutral | 4/10 | Kailera Therapeutics reported Q2 2026 financial results, highlighting a net loss of $111.3M, a cash position of $1.17B t | Aug 12, 2026 |
| AZTR | PRESS-RELEASE | neutral | 4/10 | The company highlighted preclinical data for ATR-COSF cosmetic ingredient and continued enrollment in the ATR-04 Phase 1 | Aug 12, 2026 |
| PFE | CLUSTER | bullish | 6/10 | Four Pfizer insiders traded within a week of Q2 2026 earnings. Chairman & CEO Albert Bourla and two directors made open- | Aug 12, 2026 |
| MTEX | PRESS-RELEASE | bullish | 6/10 | Mannatech reported Q2 2026 net sales of $26.7M, up $1.0M YoY, and swung to net income of $1.0M ($0.53/diluted share) fro | Aug 12, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology reported Q1 2026 earnings with an EPS of -$0.83, beating consensus of -$0.88 by 5.7%, and revenue of $20.2 | Aug 12, 2026 |
| HYPD | PRESS-RELEASE | bullish | 7/10 | Hyperion DeFi reported Q2 2026 GAAP net income of $31.0M, a second consecutive record, driven by $54.8M in non-GAAP trea | Aug 12, 2026 |
| SPRO | PRESS-RELEASE | neutral | 4/10 | Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compare | Aug 12, 2026 |
| AVBP | PRESS-RELEASE | bearish | 6/10 | ArriVent reported Q2 2026 EPS of -$1.05, a 16.7% miss vs consensus of -$0.98, with net loss widening to $49.9M from $31. | Aug 12, 2026 |